PL EN


Preferences help
enabled [disable] Abstract
Number of results
Journal
2013 | 3 | 4 | 274-277
Article title

Mięsakorak trzonu macicy jako trzeci nowotwór pacjentki – opis przypadku i omówienie aktualnych zaleceń postępowania

Content
Title variants
EN
Carcinosarcoma of the uteri as a third diagnosed malignancy – case report and the review of treatment modality
Languages of publication
PL
Abstracts
EN
Uterine carcinosarcoma is a rare epithelial malignant neoplasm. It is aggressive uterine cancer with poor survival rates. The use of adjuvant treatment seems to be beneficial. Chemotherapy should be based on paclitaxel and ifosfamide. There are ongoing clinical trials to identify potentially more active agents. The GOG phase II trial evaluating paclitaxel and carboplatin have demonstrated significant activity and acceptable toxicity. Multiple primary malignancies are diagnosed rarely. The presented patient was treated because of three independent malignancies: kidney, breast cancer and uterine carcinosarcoma.
PL
Mięsakorak trzonu macicy należy do nabłonkowych nowotworów macicy. Ma on agresywny przebieg i niekorzystne rokowanie. Zastosowanie leczenia uzupełniającego może poprawić rokowanie. Obecnie zalecanym schematem chemioterapii jest protokół zawierający paklitaksel i ifosfamid. Trwają liczne badania mające wskazać najskuteczniejszą opcję leczenia. Badania II fazy udokumentowały skuteczność schematu opartego na taksanach i pochodnych platyny przy stosunkowo małej jego toksyczności. Współistnienie kilku niezależnych nowotworów jest rzadkie. U opisanej pacjentki stwierdzono zachorowanie na trzy niezależne nowotwory: raka nerki, raka piersi i mięsakoraka trzonu macicy.
Discipline
Publisher

Journal
Year
Volume
3
Issue
4
Pages
274-277
Physical description
Contributors
  • Klinika Onkologii, Centrum Medyczne Kształcenia Podyplomowego, Europejskie Centrum Zdrowia Otwock
References
  • FIGO Committee on Gynecologic Oncology: Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int. J. Gynecol. Obstet. 2009; 105: 103-104.
  • Prat J.: FIGO staging for uterine sarcomas. Special editorial. Int. J. Gynecol. Obstet. 2009; 104: 177-178.
  • McCluggage W.G.: Uterine carcinosarcomas (malignant mixed Mullerian tumors) are metaplastic carcinomas. Int. J. Gynecol. Cancer 2002; 12: 687-690.
  • Sartori E., Bazzurini L., Gadducci A. et al.: Carcinosarcoma of the uterus: A clinicopathological multicenter CTF study. Gynecol. Oncol. 1997;67: 70-75.
  • Rose P.G., Piver M.S., Tsukada Y. et al.: Patterns of metastasis in uterine sarcoma: An autopsy study. Cancer 1989; 63: 935-938.
  • NCCN Guidelines. Uterine Neoplasms, Version 3.2012 [online: www.nccn.org].
  • Reed N.S., Mangioni C., Malmström H. et al.: Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). Eur. J. Cancer 2008; 44(6): 808-18.
  • Wolfson A.H., Brady M.F., Rocereto T. et al.: A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus. Gynecol. Oncol. 2007; 107(2): 177-85.
  • Chi D.S., Mychalczak B., Saigo P.E. et al.: The Role of Whole-Pelvic Irradiation in the Treatment of Early-Stage Uterine Carcinosarcoma. Gynecol. Oncol. 1997; 65: 493-498.
  • Sutton G., Brunetto V.L., Kilgore L. et al.: A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: A Gynecologic Oncology Group Study. Gynecol. Oncol. 2000; 79(2): 147-53.
  • Homesley H.D., Filiaci V., Markman M. et al.: Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study. J. Clin. Oncol. 2007; 25(5): 526-31.
  • Powell M.A., Filiaci V.L., Rose P.G. et al.: Phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: a Gynecologic Oncology Group study. J. Clin. Oncol. 2010; 28(16): 2727-31.
  • Ramondetta L.M. et al.: A phase II multicenter trial of paclitaxel and carboplatin in women with advanced or recurrent malignant mixed mullerian tumors (MMMT) of the uterus. J. Clin. Oncol. 2007; 25(supl.): 296s (abstr. 5589).
  • Hoskins P.J., Le N., Ellard S. et al.: Carboplatin plus paclitaxel for advanced or recurrent uterine malignant mixed mullerian tumors: The British Columbia Cancer Agency experience. Gynecol. Oncol. 2008; 108: 58-62.
  • El-Nashar S.A., Mariani A.: Uterine carcinosarcoma. Clin. Obstet. Gynecol. 2011; 54(2): 292-304.
  • Grundmann R.T., Meyer F.: [Second primary malignancy among cancer survivors-epidemiology, prognosis and clinical relevance]. Zentralbl. Chir. 2012; 137: 565-574.
  • Huang X.Y., Huang Z.L., Huang J. et al.: A case of multiple primary malignancies and investigation of family history. Oncol. Lett. 2012; 4: 931-934.
Document Type
report
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.psjd-c7c3ea7b-6f93-4536-b483-cc98eb0a346a
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.